Wei ZJ, Qiao YT, Zhou BC, Rankine AN, Zhang LX, Su YZ, Xu AM, Han WX, Luo PQ. Model established based on blood markers predicts overall survival in patients after radical resection of types II and III adenocarcinoma of the esophagogastric junction. World J Gastrointest Surg 2022; 14(8): 788-798 [PMID: 36157366 DOI: 10.4240/wjgs.v14.i8.788]
Corresponding Author of This Article
Pan-Quan Luo, MM, Surgeon, Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, No. 81 Meishan Road, Shushan District, Hefei 230022, Anhui Province, China. xamlpqdoctor@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Aug 27, 2022; 14(8): 788-798 Published online Aug 27, 2022. doi: 10.4240/wjgs.v14.i8.788
Table 1 Characteristics of the recruited patients
Characteristic
Surviving
Dead
Gender
Male
148 (78.3)
134 (80.7)
Female
41 (21.7)
32 (19.3)
Age (yr)
65.00 (60.00-71.00)
63.00 (59.00-69.25)
Tumor size
5.00 (4.00-7.00)
4.00 (2.50-5.50)
TNM stage
I-II
49 (25.9)
105 (63.3)
III
140 (74.1)
61 (36.7)
Differentiation grade
Low
59 (31.2)
70 (42.2)
High
130 (68.8)
96 (57.8)
BMI (kg/m2)
21.23 (19.88-23.85)
22.96 (20.96-25.00)
Tumor location
Siewert II
104 (55.0)
98 (59.0)
Siewert III
85 (45.0)
68 (41.0)
NLR
2.37 (1.61-3.62)
2.20 (1.55-2.86)
PLR
122.75 (87.98-182.94)
108.03 (81.43-152.54)
CEA
3.60 (1.95-9.30)
2.20 (1.44-6.85)
CA199
10.34 (5.64-20.26)
9.88 (5.75-16.88)
PNI
48.80 (45.30-53.15)
50.35 (47.20-53.45)
Albumin
41.60 (38.40-44.80)
42.40 (39.48-44.30)
Prealbumin
187.00 (153.50-234.00)
239.50 (201.75-264.25)
Neutrophil count
3.41 (2.72-4.53)
3.26 (2.38-4.48)
Platelet count
188.00 (143.00-235.50)
176.00 (145.00-219.50)
Lymphocyte count
1.43 (1.10-1.82)
1.63 (1.26-1.97)
Table 2 Univariate analysis of adenocarcinoma of the esophagogastric junction (types II and III) patients
Characteristic
Coefficient
HR (95%CI)
P value
Gender (men/women as reference)
0.078
1.081 (0.765, 1.528)
0.660
Age
0.019
1.019 (1.002, 1.037)
0.031
NLR
0.176
1.193 (1.112, 1.280)
< 0.001
Tumor size
0.178
1.195 (1.134, 1.260)
< 0.001
TNM stage
1.042
2.836 (2.046, 3.930)
< 0.001
Histologic type
0.390
1.477 (1.086, 2.009)
0.013
CA199
0.000
1.000 (0.998, 1.002)
0.948
PNI
-0.034
0.966 (0.940, 0.993)
0.013
PLR
0.003
1.003 (1.001, 1.005)
0.009
Fibrinogen
0.010
1.030 (0.970, 1.095)
0.332
Albumin
-0.289
0.557 (0.479, 1.008)
0.056
Prealbumin
-0.102
0.362 (0.271, 0.484)
< 0.001
Surgery time
0.017
1.017 (0.755, 1.369)
0.912
BMI
-0.580
0.560 (0.431, 0.727)
< 0.001
Cancerous node
0.219
1.245 (1.150, 1.347)
< 0.001
Hemoglobin
-0.006
0.994 (0.988, 1.000)
0.033
Tumor location
0.719
1.127 (0.855, 1.487)
0.397
Smoking
0.006
0.994 (0.970, 1.019)
0.624
Comorbidities
0.017
0.983 (0.953, 1.013)
0.264
Table 3 Multivariate analysis of adenocarcinoma of the esophagogastric junction (types II and III) patients
Characteristic
Coefficient
HR (95%CI)
P value
TNM stage
0.827
2.286 (1.236, 4.227)
0.008
BMI
-0.470
0.625 (0.413, 0.946)
0.026
NLR
1.092
2.979 (1.565, 5.674)
0.001
CEA
0.008
1.008 (0.997, 1.019)
0.143
Age
0.031
0.970 (0.556, 1.691)
0.914
Tumor size
0.143
1.154 (0.651, 2.045)
0.624
PNI
0.347
1.415 (0.783, 2.557)
0.250
PLR
0.040
1.041 (0.567, 1.912)
0.897
Hemoglobin
0.197
0.821 (0.479, 1.408)
0.474
Prealbumin
0.122
0.885 (0.496, 1.578)
0.678
Differentiation grade
0.073
1.075 ( 0.630, 1.836)
0.791
Cancerous node
0.084
1.088 (0.587, 2.016)
0.789
Table 4 Nomogram scoring system
NLR
Points
TNM stage
Points
BMI
Points
Low (1)
0
I and II (1)
0
Low (1)
0
High (2)
26
III and IV (2)
20
Normal (2)
58
High (3)
100
Citation: Wei ZJ, Qiao YT, Zhou BC, Rankine AN, Zhang LX, Su YZ, Xu AM, Han WX, Luo PQ. Model established based on blood markers predicts overall survival in patients after radical resection of types II and III adenocarcinoma of the esophagogastric junction. World J Gastrointest Surg 2022; 14(8): 788-798